Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | TDO2 | P48775 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10580002 | 0.93 | LMNA (0.60) | SLC6A4SLC6A3SLC6A2SIGMAR1LMNA | |
| SCHEMBL10401527 | 0.88 | SLC6A2 (0.54) | SLC6A4SLC6A3SLC6A2SIGMAR1LMNA | |
| SCHEMBL7634181 | 0.79 | SLC6A2 (0.47) | SLC6A4SLC6A3SLC6A2LMNAIDO1 | |
| Flunamine SCHEMBL2110008 | 0.79 | SLC6A4 (0.58) | SLC6A4SLC6A3SLC6A2SIGMAR1LMNA | |
| SCHEMBL4278117 | 0.79 | SLC6A4 (0.58) | SLC6A4SLC6A3SLC6A2SIGMAR1LMNA | |
| SCHEMBL4283044 | 0.79 | SLC6A2 (0.58) | SLC6A4SLC6A3SLC6A2SIGMAR1LMNA | |
| SCHEMBL423398 | 0.79 | SLC6A2 (0.62) | SLC6A4SLC6A3SLC6A2SIGMAR1LMNA | |
| SCHEMBL3336564 | 0.78 | SCN1A (0.57) | SLC6A4SLC6A3SLC6A2SIGMAR1LMNA | |
| Flunamine SCHEMBL7434697 | 0.78 | SLC6A2 (0.56) | SLC6A4SLC6A3SLC6A2SIGMAR1LMNA | |
| SCHEMBL8746929 | 0.76 | SLC6A2 (0.54) | SLC6A4SLC6A3SLC6A2SIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071124-A1 | Compounds that Inhibit Production of sAPPB and AB and Uses Thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071124-A1 | Compounds that Inhibit Production of sAPPB and AB and Uses Thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2009137597-A1 | COMPOUNDS THAT INHIBIT PRODUCTION OF sAPPβ AND Aβ AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-11-12 | — | — | WO | disclosed |
| US-6251363-B1 | ALKYLENEDIAMINES WITH FLUORINE SUBSTITUTED OXYPHENYL GROUPS | THE GENERAL HOSPITAL | 2001-06-26 | — | — | US | disclosed |
| US-6001330-A | DIAMINE DOPAMINE OR SEROTONIN LIGAND OF GIVEN FORMULA; LABELED WITH A RADIONUCLIDE AND ADMINISTERED FOR IMAGING DOPAMINE NEURONS IN A MAMMAL; TREATING COCAINE ABUSE | GENERAL HOSPITAL CORPORATION, THE | 1999-12-14 | — | — | US | disclosed |
| WO-1999012893-A1 | DIAGNOSTIC AND THERAPEUTIC ALKYLENEDIAMINE COMPOUNDS AND PROCESS | ELMALEH DAVID R (US) | 1999-03-18 | — | — | WO | disclosed |
| US-5171752-A | BENZHYDRYL DERIVATIVES HAVING CALMODULIN INHIBITOR PROPERTIES | AKZO N.V. (NL) | 1992-12-15 | — | — | US | disclosed |
| EP-0467435-A2 | Benzhydryl derivatives having calmodulin inhibitor properties | Akzo Nobel N.V. (NL) | 1992-01-22 | — | — | EP | disclosed |
| US-4957927-A | (Diarylmethoxy alkyl)-1-pyrrolidines and piperidines having cardiovascular activity | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1990-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071124-A1 | Compounds that Inhibit Production of sAPPB and AB and Uses Thereof | SAP30BP, APP, BACE1 | SLC6A4 4300/4885SLC6A3 2796/4885SLC6A2 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.